# Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study

> **NCT06451302** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Yizhuo Zhang** · enrollment: 100 (estimated)

## Conditions studied

- Ewing Sarcoma
- Risk Stratification

## Interventions

- **DRUG:** cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide

## Key facts

- **NCT ID:** NCT06451302
- **Lead sponsor:** Yizhuo Zhang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06451302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06451302, "Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06451302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*